Tang Capital Management GHRS Position
Exited9-Fund ConvergenceTang Capital Management exited their position in GH Research PLC (GHRS) in Q4 2025, after holding the stock for 2 quarters.
The position was first reported in Q3 2025 and has been tracked across 2 quarterly 13F filings.
GHRS is a convergence signal: 9 specialist biotech funds hold this stock, suggesting high institutional conviction.
Short interest stands at 12.9% of float with 11.6 days to cover, indicating significant bearish positioning against the stock.
About GH Research PLC
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate; and GH003, an intranasal 5-MeO-DMT product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.
Full company profile →Short Interest
12.9%
11.6 days to cover
Tang Capital Management GHRS Position History
Frequently Asked Questions
Does Tang Capital Management own GHRS?
No. Tang Capital Management exited their position in GH Research PLC (GHRS) in Q4 2025. They previously held the stock for 2 quarters.
How many hedge funds own GHRS?
9 specialist biotech hedge funds currently hold GHRS, including BVF Partners, RA Capital Management, RTW Investments and 6 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Tang Capital Management first buy GHRS?
Tang Capital Management's position in GHRS was first reported in Q3 2025. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Tang Capital Management's GHRS position increasing or decreasing?
Tang Capital Management completely exited their GHRS position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
GHRSCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Tang Capital ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →